While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Flu vaccine makers may face a last-minute scramble to produce enough doses after an FDA advisory committee meeting was ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Merck & Co. Inc. closed 32.72% below its 52-week high of $134.63, which the company achieved on June 25th.

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

We recently published a list of 10 Best Affordable Dividend Stocks to Buy According to Hedge Funds. In this article, we are ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...

NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.